The Truth Wears Off

The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis.     However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken in time, perpetuates a myth about the new…

FDA Expands Market for Another Toxic Antipsychotic

According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’…

Making a Killing–Marketing Exercises by Dr. Carl Elliott

The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research.